Introduction
The metastatic spread of tumor cells is responsible for the majority of cancer deaths. Similarly, the mortality of breast cancer is also largely the result of metastasis, the common sites being the lymph nodes, lung, liver and bone. Lymph node metastasis is one of the most important adverse prognostic factors for breast carcinomas. 1 In principle, cancer cells spread through the body by different mechanisms, such as direct invasion of surrounding tissue, via the blood vascular system (hematogenous metastasis) and/or via the lymphatic system (lymphatic metastasis). The ability to block the signaling system that enables the spread of cancer would be a major step forward in the prevention of tumor metastasis, and would consequently reduce both morbidity and mortality.
Vascular endothelial growth factor-C (VEGF-C) is the major lymphangiogenic factor expressed in certain normal tissues, as exemplified by large intestine, mammary duct, prostate, thyroid and ovary, and cardiac and skeletal muscle as evaluated by immunohistochemistry. 2 In addition, VEGF-C is also expressed in a variety of malignant tumors including mammary cancer. 3 Furthermore, overexpression of VEGF-C has been reported to be associated with a poor prognosis and lymph node metastasis in breast cancer patients. 4, 5 A number of animal studies using cell lines [6] [7] [8] and transgenic mice 9 have been conducted in an attempt to demonstrate that VEGF-C overexpression is able to promote cancer metastasis. Thus, tumor cell-derived VEGF-C is thought to enhance lymph node metastasis. Moreover, VEGF-A is well known to exert a crucial role in tumor angiogenesis. 10 An adequate blood supply is required to sustain the uncontrolled cell proliferation characteristic of malignant tumors, and tumorigenesis and metastasis have been associated with angiogenesis in tumors. 10 Therefore, lymphangiogenesis and angiogenesis in tumors have become potential targets for cancer therapy. In addition, the number of CD8 þ T cells and dendritic cells is significantly elevated in inoculated murine mammary tumor cells stably transfected with VEGF-C siRNA, suggesting that VEGF-C modulates the immune response. 11 On the basis of the above evidence, we used an immunocompetent mammary cancer model in our experiment.
Over the past few years RNA interference has become the most widely used technology for gene silencing. In the present study, we examined whether inhibition of VEGF-C or VEGF-A by gene silencing using vectors expressing short interfering RNA (siRNA) might lead to suppression of lymphatic and/or hematogenous metastasis in a mouse immunocompetent mammary cancer model having a metastatic spectrum similar to that seen in human breast cancers. Although a paramount challenge for therapy targeting both lymphatic and hematogenous metastasis is to design combination protocols that counteract both VEGF-C and VEGF-A, we also tried combination gene therapy of siRNA expression vectors simultaneously targeting VEGF-C and VEGF-A.
Materials and methods

Cell line
Mouse mammary tumor virus, purified from medium in which Jyg-MC cells (established from mammary tumors of the Chinese wild mouse) were grown, was inoculated into the inguinal mammary glands of female BALB/c mice, resulting in the development of mammary carcinomas. 12 The BJMC3879 mammary adenocarcinoma cell line was subsequently derived from a metastatic focus within a lymph node from one of the inoculated mice and the cell line continues to show a high metastatic propensity, especially to lymph nodes and lungs. [13] [14] [15] We maintain the BJMC3879 cell line in the RPMI-1640 medium or Dulbecco's modified Eagle's medium containing 10% fetal bovine serum supplemented with streptomycin/penicillin in an incubator at 37 1C and under a 5% CO 2 atmosphere.
Animals
A total of 50 6-week-old female BALB/c mice were used in this study (Japan SLC Inc., Hamamatsu, Japan). The animals were housed not more than 5 per plastic cage on a wood chip bedding with free access to water and food and maintained under conditions of controlled temperature (21 ± 2 1C), humidity (50 ± 10%) and lighting (12-12 h light-dark cycle). All were held for a 1-week acclimatization period before test initiation; all manipulations and treatments of mice were performed in accordance with the procedures outlined in the Guide for the Care and Use of Laboratory Animals at Osaka Medical College. At the termination of the study, all mice were euthanized under isoflurane anesthesia.
siRNA expression vectors
To construct short hairpin RNAs (shRNA) targeting mouse VEGF-C, the following oligonucleotides were designed: VEGF-C1, 5
0 -GCAUGAACACCAGCACAGGU UucaagagAACCUGUGCUGGUGUUCAUGC-3 0 ; VEGF-C2, 5
0 -GAGCUGGAUGAAGACACCUGUucaagagACA GGUGUCUUCAUCCAGCUC-3 0 ; and VEGF-C3, 5 0 -GA UGAGAAUACAUGUCAGUGUucaagagACACUGACA UGUAUUCUCAUC-3 0 . Each oligonucleotide contains a 21-nucleotide sequence in sense and antisense orientation separated by a 7-nucleotide spacer (indicated above by small letters in italics). Each complementary oligonucleotide was annealed and ligated into a BbsI/BbsI-digested psiRNA-h7SKGFP-zeo vector (InvivoGen Inc., San Diego, CA). This vector contains the human 7SK promoter (RNA polymerase III promoter), which can generate large amounts of shRNAs. 16 Positive clones were identified by restriction digestion and confirmed by sequencing. A vector targeting mouse VEGF-A (psiRNA-mVEGF-A) and a control psiRNA vector (psiRNA-SCR) were purchased from InvivoGen Inc. The VEGF-A siRNA sequence is as follows 5 0 -GCUA CUGCCGUCCAAUUGAucaagagUCAAUUGGACGG CAGUAGC-3 0 . 17 The control psiRNA-SCR vector contains a scrambled sequence that presents no homology with any human or mouse mRNAs. For simplicity, in this paper, the therapeutic vectors are referred to as psiRNA-VEGF-C1, psiRNA-VEGF-C2, psiRNA-VEGF-C3 and psiRNA-VEGF-A vectors. The pGL3-control vector (Promega, Madison, WI), which encodes the firefly luciferase gene, was used as the reporter gene.
Selection of functional VEGF-C siRNA sequence In the transfection process, BJMC3879 cells (1 Â 10 7 ) were suspended in 100 ml of Nucleofector V solution (amaxa, GmbH, Ko¨ln, Germany) and 5 mg of psiRNA-VEGF-C1, psiRNA-VEGF-C2, psiRNA-VEGF-C3 or control psiR-NA-SCR vector was added to each cell suspension. We then conducted gene electrotransfer using Nucleofector (amaxa) with program no. T03 for BJMC3879 cells. 18 Subsequently, the cells were plated in six-well plates. At 48 h post-transfection, the cells were collected and total RNA was extracted using an RNeasy Mini Kit (Qiagen, GmbH, Hilden, Germany). cDNAs were synthesized using a Transcriptor First Strand cDNA Synthesis Kit (Roche Diagnostics, GmbH, Manheim, Germany). Realtime reverse transcription-PCR (RT-PCR) was performed using a LightCycler (Roche Diagnostics) as follows: an initial step at 95 1C for 10 min, followed by 40 cycles of 10 s at 95 1C, 10 s at 60 1C and 10 s at 72 1C. The primers for mouse VEGF-C were 5 0 -AACGTGTCCAAGAAAT CAG-3 0 and TGGATCACAATGCTTCAGT-3 0 (157 bp product), whereas those for mouse glyceraldehyde-3-phsophate dehydrogenase, used as a reference control, were 5 0 -TGGCCTTCCGTGTTCCTACC-3 0 and 5 0 -AGC CCAAGATGCCCTTCAGT-3 0 (135 bp product). The relative expression levels of VEGF-C mRNA were siRNA vectors against VEGF inhibit metastasis M-A Shibata et al calculated using a 2
ÀDDCt method, 19 which is based on the fact that the difference in threshold cycles (DC t ) between VEGF-C and glyceraldehyde-3-phsophate dehydrogenase is proportional to the relative expression level of the gene of interest. Of the psiRNA-VEGF-C1, psiRNA-VEGF-C2 and psiRNA-VEGF-C3 vectors, the vector that showed strong knockdown efficiency of relative VEGF-C levels to the relative VEGF-C levels of psiRNA-SCR was selected. This was psiRNA-VEGF-C1.
Validation study for siRNA-VEGF-C The psiRNA-VEGF-C1 vector (VEGF-C1) was further examined for validation of knockdown as described below. siRNA-VEGF-C1 oligonucleotides were synthesized and the 3 0 -sense terminus was labeled with Alexa-488. The sequence of siRNA for VEGF-C1 was as follows 5 0 -AUGAACACCAGCACAGGUUdTdT-3 0 and 5 0 -AAC CUGUGCUGGUGUUCAUdGdC-3 0 . Negative siRNA control, labeled with Cy3, was purchased from Qiagen. BJMC3879 cells (8 Â 10 4 ) were plated in a well of a 24-well plate and transfected with 25 nM siRNA-VEGF-C1 or 25 nM negative siRNA control using transfection reagent (HyperFect; Qiagen). At 24 h post-transfection, the culture medium was replaced with phosphate-buffered saline containing 10% fetal bovine serum, and light and dark fields were photographed under an inverted fluorescence microscope with a 470/40 nm filter for VEGF-C1-Alexa488 and a 540/10 nm filter for negative siRNA-Cy3. The cells were then collected and used in real-time RT-PCR. We confirmed the knockdown of VEGF-C levels using real-time RT-PCR as described above. Transfection efficiency was determined by counting transfected cells and total cells in the images.
In vivo gene electrotransfer of reporter luciferase gene BJMC3879 cells (5 Â 10 6 cells per 0.3 ml in PBS) were inoculated subcutaneously into the right inguinal region of 10 female BALB/c mice. Five weeks later, when the tumors had reached approximately 0.8-1.0 cm along the major axis, a total volume of 100 ml saline containing 50 mg of pGL3 vector (luciferase expression vector, 0.5 mg ml À1 saline) was slowly injected directly into the tumors using a 27-gauge needle while the animals were under isoflurane anesthesia. Gene electrotransfer was performed immediately after the injection by applying a conductive gel (Echo Jelly; Aloka Co., Ltd, Tokyo, Japan) topically to the unshaved skin over the tumor and to the surface of the electrode plates. Electric pulses were delivered directly into the tumor via 'forceps' platinum plate electrodes (CUY650-10; Nepa Gene Co., Ltd, Ichikawa, Japan) using a CUY21EDIT square-wave electropulser (Nepa Gene Co., Ltd). Although the parameters for optimal gene electrotransfer (intratumoral injection of 50 mg plasmid, 8 pulses with a pulse length of 20 ms at 100 V) had been previously determined by us, 13, 15, 18, 20 the electropulser device has since been replaced, and thus updated optimal conditions were determined using the pGL3 luciferase expression vector. Two mice each received 25, 50, 75, 100 and 125 V per treatment. Under isoflurane inhalation anesthesia, the mice were injected intraperitoneally with D-luciferin salts at 3 mg per mouse, and then bioluminescence imaging with a Photon Imager (Biospace Measures, Paris, France) was performed on day 3 after the gene transfer. Acquisition time was 15 min and bioluminescent signals were quantified using Photovision software (Biospace Measures).
In vivo siRNA gene therapy targeting VEGF-C and/or VEGF-A BJMC3879 cells established from the BALB/c mouse strain were inoculated into the right inguinal region of 40 female BALB/c mice. The animals were then randomly allocated into 4 groups of 10 mice each, namely the psiRNA-VEGF-C, psiRNA-VEGF-A, psiRNA-VEGF-C þ psiRNA-VEGF-A (psiRNA-VEGF-C þ A) or psiRNA-SCR (control) groups. Two weeks post-inoculation, when the tumors had reached 0.1-0.3 cm in diameter, we injected psiRNA-VEGF-C, psiRNA-VEGF-A, psiRNA-VEGF-C þ A or psiRNA-SCR directly into the tumors and then immediately performed in vivo gene electrotransfer as described above.
We used a vector concentration of 0.5 mg ml À1 saline; when using the combined vector treatment, 1.0 mg ml À1 each of the psiRNA-VEGF-C and psiRNA-VEGF-A vectors was mixed with the same volume to yield a final combined concentration of 0.5 mg ml
À1
. The vectors were injected using a 27-gauge needle while the animals were under isoflurane anesthesia. A total volume of 150 ml was introduced into larger tumors, whereas smaller tumors of 0.6-0.7 cm in diameter were infused until we detected a leakage of the vector solution. The conditions for gene electrotransfer used in the present study were intratumoral injection of 50-75 mg plasmid (100-150 ml, dependent on tumor size as mentioned above) and eight pulses with a pulse length of 20 ms at 100 V. Vector injection and gene electrotransfer were performed once a week for 8 weeks.
Using calipers, we measured the size of each treated mammary tumor weekly and calculated tumor volumes using the formula maximum diameter Â (minimum diameter) 2 Â 0.4. 21 Individual body weights were also recorded at weekly intervals. After 8 weeks of treatment, all mice were euthanized, and the mammary tumors and certain lymph nodes (that is, nodes from axillary and femoral regions as well as any other nodes that appeared abnormal) were removed. We then immediately fixed a portion of each tissue sample in 10% phosphate-buffered formalin and processed through to paraffin embedding; an additional portion of each tumor was also immediately frozen in liquid nitrogen for molecular analysis. Lungs were routinely inflated with the fixative, excised and immersed in the fixative. We subsequently trimmed and examined all lobes for metastatic foci before processing through histology, where they were cut into 4-mm slices and stained with hematoxylin and eosin for histopathological examination.
Lymphatic and blood microvascular density in mammary tumors
To quantitatively assess lymphatic and blood microvessel density in the primary mammary carcinomas, we used the siRNA vectors against VEGF inhibit metastasis M-A Shibata et al avidin-biotin immunohistochemical complex method (LSAB kit; DakoCytomation). A hamster anti-podoplanin monoclonal antibody (AngioBio Co., Del Mar, CA), against a lymphatic endothelium marker, and a rabbit polyclonal antibody against CD31 (Lab Vision Co., CA), a specific marker for blood vessel endothelium, were used. The number of podoplanin-positive lymphatic vessels containing intra-lumenal tumor cells was also counted and expressed as the average ± s.d. In addition, the number of CD31-positive blood microvessels was counted as previously described. 22 Briefly, the slides were scanned at low-power ( Â 100) magnification to identify those areas having the highest number of vessels; the five areas of highest microvascular density were then selected and counted at higher ( Â 200-400) magnification to obtain mean ± s.d. values.
Statistical analyses
Significant differences in the quantitative data between groups were analyzed using the Student's t-test by the method of Welch, which provides for insufficient homogeneity of variance. The differences in metastatic incidence were examined by Fisher's exact probability test, with Po0.05 or Po0.01 considered to represent a statistically significant difference.
Results
Selection of functional VEGF-C siRNA sequence As shown in Figure 1a , the knockdown ratio in BJMC3879 cells was 40% for the psiRNA-VEGF-C1 and psiRNA-VEGF-C2 vectors, and 20% for psiRNA-VEGF-C3. Transfection efficiency was 51%. Although psiRNA-VEGF-C1 and psiRNA-VEGF-C2 showed a similar knockdown efficiency, the psiRNA-VEGF-C1 vector was chosen because of less variation in the knockdown efficiency. Next, we conducted a validation study in BJMC3879 cells transfected with VEGF-C1 siRNA oligonucleotides labeled with Alexa488 or negative control siRNA oligonucleotides labeled with Cy3. The level of VEGF-C mRNA was 49% lower than the levels of negative control siRNA (Figure 1b) . The mean transfection efficiency was approximately 53%. The psiRNA-VEGF-C1 vector was chosen for the in vivo experiment.
Efficiency of in vivo gene electrotransfer into mammary carcinomas Mammary carcinomas were injected with pGL3 luciferase expression vector and then immediately subjected to gene electrotransfer at 25, 50, 75, 100 or 125 V under fixed conditions of 20 ms per pulse length and eight pulses. At 3 days after gene transfer, the luminescent signal was strongest at 100 V ( Figure 2a) . As can be seen in Figure 2b , bioluminescence imaging of mammary tumors showed that the luminescent signal was strong at 75 V, and particularly at 100 V. As the highest mean photon count was obtained at 100 V, this voltage was chosen for gene electrotransfer in the in vivo siRNA experiment in the mammary carcinoma model.
Body weights and tumor growth in gene therapy using siRNA targeting VEGF-C and/or VEGF-A One animal in the psiRNA-VEGF-C group died because of high dose of anesthetic at week 6 during gene electrotransfer and thus this animal was excluded from the histopathological examination. The weight gain of mice treated with therapeutic siRNA was significantly lower than that observed in the psiRNA-SCR control group (Figure 3a) . However, the differences were slight (3-7% reduction compared with the controls) and the general condition of the animals was good throughout the experiment. The body weights at week 8 (the end of the study) were as follows: psiRNA-SCR group, 26.1±2.7 g; psiRNA-VEGF-C group, 25.2±0.9 g; psiRNA-VEGF-A group, 24.3 ± 1.3 g; and psiRNA-VEGF-C þ A group, 25.0 ± 0.9 g. Data for tumor volumes are presented in Figure 3b . Tumor volume increases were suppressed in the psiRNA-VEGF-C, psiRNA-VEGF-A, and psiRNA-VEGF-C þ A groups from week 2 compared with the psiRNA-SCR group. Tumor volume increases were significantly decreased from week 3 to the end of the study in all treatment groups with the exception of the Metastasis of mammary tumors treated with psiRNA-VEGF-C and/or psiRNA-VEGF-A Histopathologically, the implanted mammary carcinomas proved to be moderately differentiated adenocarcinomas.
Metastasis to lymph nodes. All the control mice (100%) treated with psiRNA-SCR developed metastasis to the lymph nodes (Figures 2c and d) , whereas some mice in the therapeutic groups did not have lymph node metastases (Figures 2e and f) . The incidence of metastasis dropped to 50% in the psiRNA-VEGF-C group, 60% in the psiRNA-VEGF-A group and 33% in the psiRNA-VEGF-C þ A group (Figure 4a ). As shown in Figures  4a and b , both the incidence and the overall number of lymph node metastases per mouse were significantly lower in the psiRNA-VEGF-C, psiRNA-VEGF-A and psiR-NA-VEGF-C þ A groups compared with the siRNA-SCR control mice.
Metastasis to lungs. Metastatic tumor cells were observed in both interstitial and blood capillaries. As shown in Figure 4c , in contrast to the lymph nodes, the psiRNA-VEGF-C þ A group was the only therapeutic group that showed a tendency for decreased metastasis (78%) compared with the siRNA-SCR group (100%).
Histopathologically, large metastatic lung nodules tended to be few in the siRNA-VEGF-C þ A group ( Figure 2h ) compared with the siRNA-SCR group (Figure 2g ). Quantitative measurements of the numbers of metastatic lung nodules4250 mm per mouse confirmed the significant inhibition of metastasis upon exposure to siRNA-VEGF-C þ A (Figure 4d ), but no significant differences were found in the numbers of metastatic lung nodules between mice receiving siRNA-SCR and those transfected with siRNA-VEGF-C or siRNA-VEGF-A alone.
Lymphatic and blood microvessel density in treated mammary tumors
The lymphatic microvessels in the mammary tumors were stained with anti-podoplanin antibody, as demonstrated in Figures 5a-d . Lymphatic vessels were well developed in the outer, superficial layers of the mammary tumors in a somewhat hexagonal network pattern in all groups. Frequently, tumor cells within the lumina of dilated lymphatic vessels in the tumors were observed in both control ( Figure 5a ) and treated animals (Figures 5b-d) .
As shown in Figure 6a , the number of lymphatic vessels having intralumenal cancer cells was significantly lower in all groups (psiRNA-VEGF-C, psiRNA-VEGF-C, psiRNA-VEGF-A and psiRNA-VEGF-C þ A groups) compared with the psiRNA-SCR group, indicating a suppression in migration of cancer cells into the lymphatic vessels of the tumor tissues. psiRNA-VEGF-C+A * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * * Figure 3 Body weights (a) and mammary tumor volumes (b) in female BALB/c mice treated with psiRNA-SCR (control), psiRNA-VEGF-C, psiRNA-VEGF-A or psiRNA-VEGF-C þ A (combination therapy). The body weights of mice treated with therapeutic siRNA were lower than the control mice treated with psiRNA-SCR (a). However, there were no statistical differences among groups at week 8 (termination of the study). Tumor volume increases were suppressed in mice transfected with psiRNA-VEGF-C, psiRNA-VEGF-A or psiRNA-VEGF-C þ A compared with psiRNA-SCRtreated control mice. However, at week 8, significantly suppressed tumor volumes were observed only in the psiRNA-VEGF-C and psiRNA-VEGF-C þ A groups. Data represent mean±s.d. *Po0.05; **Po0.01 compared with psiRNA-SCR controls. 
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Microvessel density, as determined by immunohistochemical analysis with the blood vessel endothelial cell marker CD31 (Figures 5e-h) , was significantly lower in all groups given therapeutic siRNA compared with the siRNA-SCR group (Figure 6b) .
Discussion
In the present study, the siRNA expression vectors targeting VEGF-C or VEGF-A strongly suppressed lymph node metastasis in our immunocompetent metastatic mammary cancer model. In addition, combination of the vectors targeting VEGF-C and VEGF-A significantly inhibited the multiplicity of lung metastatic foci as well as lymph node metastasis. Treatment with siRNA-VEGF-A or with the combined vectors (siRNA-VEGF-C þ A) significantly reduced tumor volume (tumor growth). As Carter et al. 23 have reported that once breast cancers reach 4 cm or larger, the chance of tumor recurrence and/or metastasis increases dramatically, the reduction in tumor volume by siRNA vectors seen in the present study can be clinically significant.
siRNAs have been used against cancer targets, either as synthetic RNA oligonucleotides or as vector-encoding shRNAs. shRNAs are expected to be efficiently transcribed and subsequently processed to yield the mature, active form of siRNAs. The great majority of siRNA expression vectors that have been described for the expression of shRNAs contain RNA polymerase III promoters, such as H1, U6 or 7SK promoters, which generate high amounts of shRNAs. siRNA expression No. of lung metastasis/mouse * * * * * * * * * * * * Figure 4 Quantitative analysis of lymph node metastasis (a, b) and lung metastasis (c, d) in mice treated with psiRNA-SCR, psiRNA-VEGF-C, psiRNA-VEGF-A or psiRNA-VEGF-C þ A. The incidence of lymph node metastasis was 100% in the psiRNA-SCR group, whereas siRNA-treated groups showed significantly lower incidences (*Po0.05, **Po0.01) (a). The number of lymph nodes with metastases per mouse was also significantly lower in mice receiving psiRNA-VEGF-C, psiRNA-VEGF-A or psiRNA-VEGF-C þ A (**Po0.01) (b). Incidence of lung metastasis was similar between control and therapeutic groups (c). However, the number of lung metastatic nodules 4250 mm was significantly lower in the psiRNA-VEGF-C þ A group only (*Po0.05) (d). Data represent mean±s.d. *Po0.05; **Po0.01 compared with the psiRNA-SCR controls. vectors may be advantageous for cancer therapy, especially in situations where long-term production from a conveniently transduced tissue can be effected. In addition, we applied in vivo gene electrotransfer (in vivo electroporation) as means of siRNA vector introduction. Although in vivo gene electrotransfer was previously believed to have very low transfection efficiency, it was recently reported that, under suitable conditions, transduction was found to be approximately equivalent to that using an adenoviral vector concentration of 10 6 transduction units ml
À1
. Although in vivo gene electrotransfer was not as effective when compared with higher viral concentrations, 24 the technique offers some attractive advantages over the use of viral vectors. In the first place, as vector immunogenicity is not an issue, accumulation of gene transduction is possible through repeated transfections. In addition, the vector is much easier to manipulate than a viral vector, and the procedure is safe in vivo and does not depend on cell cycles within target tissues. Several studies have further reported the efficacy of using in vivo gene electrotransfer in animal cancer models. 13, 18, [25] [26] [27] [28] Tumor cell dissemination is mediated by a number of mechanisms, including direct invasion into local tissue, lymphatic spread and hematogenous spread. In general, the most common pathway of initial dissemination is through the lymphatics, with patterns of spread through afferent ducts. 29 The lymphatic capillaries present in tissues and tumors provide entrance into the lymphatic system, allowing cancer cell migration to the lymph nodes. VEGF-C expression has been shown to correlate with lymph node metastasis in a variety of human cancers, including breast neoplasms. 3, 30 In many animal models of cancer, VEGF-C has been shown to enhance tumor lymphangiogenesis, the metastatic spread of tumor cells to lymph nodes and, in some cases, distant organ metastasis. 31 Downregulation of VEGF-C using siRNA has been shown to reduce lymph node and lung metastases in murine mammary cancer models. 11 In addition, VEGFR-3, the VEGF-C receptor, is predominantly expressed on lymphatic endothelial cells, 32 and VEGF-C-dependent activation of VEGFR-3 stimulates the growth of lymph endothelial cells and lymphatics. 33 Blockade of VEGFR-3 signaling by soluble VEGFR-3 inhibits lymphangiogenesis and lymph node metastasis in experimental animal cancer models. 8, 34, 35 In the present study, we observed a significant decrease in the number of lymphatic vessels with tumor cells in their lumina in the psiRNA-VEGF-C, psiRNA-VEGF-A and psiRNA-VEGF-C þ A groups compared with the psiRNA-SCR control group, indicating an inhibitory effect on migration into tumor lymphatic vessels. In fact, lymph node metastasis was significantly decreased in all these therapeutic groups. Interestingly, not only psiRNA-VEGF-C but also psiRNA-VEGF-A inhibited lymph node metastasis and was associated with a decrease in the number of lymphatic vessels with tumor cells in their lumina. It is well known that tumor angiogenesis is primarily driven by VEGF-A. 36 However, recent studies have shown that VEGF-A can also enhance lymphangiogenesis. 37, 38 In addition, overexpression of VEGF-A has been shown to promote the survival, migration and invasiveness of breast cancer cells. 39 Indeed, inhibition of VEGF-A expression is associated with decreases in tumor lymphangiogenesis and metastasis. 40, 41 Moreover, a reduction in metastasis by downregulation of VEGF-A may be responsible for inhibition of angiogenesis and lymphangiogenesis in tumors, prevention of angiogenic switching in micrometastases and blockage of macrophage recruitment. 42, 43 AntiVEGF-A therapy reduces lymphatic vessels and expression of VEGFR-3 in an orthotopic breast tumor model, 41 which may be the mechanism for the anti-metastasis effect.
Cancer cells metastasize to distal sites through the vascular system as well as through the lymphatic system. We also found a significant decrease in microvessel density in the psiRNA-VEGF-C, psiRNA-VEGF-A and psiRNA-VEGF-C þ A groups.VEGF-A is a key anigiogenic factor that functions by binding to and activating siRNA vectors against VEGF inhibit metastasis M-A Shibata et al VEGFR-2. In the present study, siRNA-VEGF-A successfully decreased tumor microvessel density. Furthermore, psiRNA-VEGF-C also significantly inhibited tumor microvessel density. The capacity of VEGF-C to bind to and activate VEGFR-2 may explain this finding. 33, 44 In fact, VEGF-C also stimulates angiogenesis under certain experimental conditions. 45 The present study demonstrated that all therapeutic groups showed significant suppression of lymph node metastasis. However, for lung metastasis, only the combination treatment (psiRNA-VEGF-C þ A) exerted a significant decrease in multiplicity of lung metastatic nodules. Although the initial pathway of lung metastasis may also be through the lymphatic system, cancer cells then influx into the left subclavian vein, pass through the right ventricle, and then settle and grow in the lung tissue. As described above, since both VEGF-C and VEGF-A have been reported to be associated with tumor metastasis, summation or synergistic effects of the combination treatment targeting VEGF-C and VEGF-A may be at play. Regardless of the mechanism involved, as the combination therapy of psiRNA-VEGF-C and psiRNA-VEGF-A exhibited summative or synergistic effects on lung metastasis, this combination therapy may have high clinical significance. Further investigation is necessary to explore this possibility.
In conclusion, we have demonstrated that combination therapy with siRNA vectors targeting VEGF-C and VEGF-A significantly suppresses tumor growth and both lymph node and lung metastasis in a mouse mammary cancer model. We believe the anti-metastatic activity of combination therapy with siRNA expression vectors targeting VEGF-C and VEGF-A may be of high clinical significance for the treatment of metastatic human breast cancer.
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